RU2539729C2 - Моноклональные антитела против активированного протеина с - Google Patents

Моноклональные антитела против активированного протеина с Download PDF

Info

Publication number
RU2539729C2
RU2539729C2 RU2010121148/10A RU2010121148A RU2539729C2 RU 2539729 C2 RU2539729 C2 RU 2539729C2 RU 2010121148/10 A RU2010121148/10 A RU 2010121148/10A RU 2010121148 A RU2010121148 A RU 2010121148A RU 2539729 C2 RU2539729 C2 RU 2539729C2
Authority
RU
Russia
Prior art keywords
antibody
apc
subject
protein
activated protein
Prior art date
Application number
RU2010121148/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2010121148A (ru
Inventor
Дзун СЮЙ
Чарльз ЭСМОН
Original Assignee
Оклахома Медикал Рисерч Фаундейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Оклахома Медикал Рисерч Фаундейшн filed Critical Оклахома Медикал Рисерч Фаундейшн
Publication of RU2010121148A publication Critical patent/RU2010121148A/ru
Application granted granted Critical
Publication of RU2539729C2 publication Critical patent/RU2539729C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
RU2010121148/10A 2007-10-26 2008-10-24 Моноклональные антитела против активированного протеина с RU2539729C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98309207P 2007-10-26 2007-10-26
US60/983,092 2007-10-26
PCT/US2008/081110 WO2009055669A2 (en) 2007-10-26 2008-10-24 Monoclonal antibodies against activated and unactivated protein c

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2012150953/10A Division RU2012150953A (ru) 2007-10-26 2012-11-27 Моноклональные антитела против активированного протеина с

Publications (2)

Publication Number Publication Date
RU2010121148A RU2010121148A (ru) 2011-12-10
RU2539729C2 true RU2539729C2 (ru) 2015-01-27

Family

ID=40289112

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2010121148/10A RU2539729C2 (ru) 2007-10-26 2008-10-24 Моноклональные антитела против активированного протеина с
RU2012150953/10A RU2012150953A (ru) 2007-10-26 2012-11-27 Моноклональные антитела против активированного протеина с

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2012150953/10A RU2012150953A (ru) 2007-10-26 2012-11-27 Моноклональные антитела против активированного протеина с

Country Status (13)

Country Link
US (3) US8153766B2 (enExample)
EP (1) EP2205638B1 (enExample)
JP (3) JP2011500843A (enExample)
KR (2) KR20150092358A (enExample)
CN (3) CN105153308A (enExample)
AU (1) AU2008316661B2 (enExample)
BR (1) BRPI0818865A2 (enExample)
CA (1) CA2703738C (enExample)
IL (2) IL205284A (enExample)
MX (1) MX2010004615A (enExample)
RU (2) RU2539729C2 (enExample)
WO (1) WO2009055669A2 (enExample)
ZA (1) ZA201105704B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2824515C1 (ru) * 2021-07-13 2024-08-08 Оклахома Медикал Рисерч Фаундейшн Моноклональное антитело к активированному белку с человека и его получение и применение

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9801362B2 (en) * 2012-03-16 2017-10-31 Regeneron Pharmaceuticals, Inc. Non-human animals expressing pH-sensitive immunoglobulin sequences
CN104936618A (zh) 2012-11-29 2015-09-23 拜尔健康护理有限责任公司 针对活化蛋白c的人源化单克隆抗体及其用途
MX2015006424A (es) * 2012-11-29 2015-08-14 Bayer Healthcare Llc Anticuerpos monoclonales contra una proteina activada c (apc).
TWI673063B (zh) * 2013-09-20 2019-10-01 日商中外製藥股份有限公司 抗蛋白ｃ抗體之出血性疾病的治療
GB201322091D0 (en) 2013-12-13 2014-01-29 Cambridge Entpr Ltd Modified serpins for the treatment of bleeding disorders
WO2015179435A1 (en) 2014-05-19 2015-11-26 Bayer Healthcare Llc Optimized humanized monoclonal antibodies against activated protein c and uses thereof
US11077187B2 (en) * 2015-11-17 2021-08-03 Oklahoma Medical Research Foundation Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
EP3559035A1 (en) 2016-12-21 2019-10-30 TeneoBio, Inc. Anti-bcma heavy chain-only antibodies
CN110891971B (zh) 2017-06-20 2024-01-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
WO2019009407A1 (ja) * 2017-07-07 2019-01-10 第一三共株式会社 抗プロテインｃ抗体
US11447546B2 (en) 2017-07-20 2022-09-20 Nbe-Therapeutics Ag Human antibodies binding to ROR2
EP3682247B1 (en) * 2017-09-13 2022-02-09 B.R.A.H.M.S GmbH Proadrenomedullin as a marker for abnormal platelet levels
WO2020051277A1 (en) * 2018-09-06 2020-03-12 Board Of Regents, The University Of Texas System Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein c receptor (epcr)
EP3867645B1 (en) * 2018-10-18 2024-06-05 Oklahoma Medical Research Foundation Biomarkers for a systemic lupus erythematosus (sle) disease activity immune index that characterizes disease activity
CN109897108B (zh) * 2019-03-11 2021-04-02 上海恒赛生物科技有限公司 抗人内皮蛋白c受体的羊驼单域抗体及应用
EP3871689A1 (en) 2020-02-26 2021-09-01 sphingotec GmbH Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c
CN115611986B (zh) * 2021-07-13 2025-08-12 上海莱士血液制品股份有限公司 针对人活化蛋白c的单克隆抗体及其制备和应用
KR20240152428A (ko) * 2022-03-04 2024-10-21 주식회사 코애귤런트테라퓨틱스 활성화된 단백질 c에 대한 인간 항체 및 이의 용도
CN119136834A (zh) * 2022-03-04 2024-12-13 凝血剂治疗公司 针对活化蛋白c的骆驼科动物抗体及其用途
CN118370814A (zh) * 2023-01-20 2024-07-23 上海莱士血液制品股份有限公司 一种抗aPC单克隆抗体的制剂及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000102A1 (en) * 1991-06-24 1993-01-07 The Scripps Research Institute Apc polypeptides and anti-peptide antibodies, diagnostic methods and systems for inhibitng apc, and therapeutic methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202253A (en) * 1988-12-30 1993-04-13 Oklahoma Medical Research Foundation Monoclonal antibody specific for protein C and antibody purification method
US7247453B1 (en) * 1988-12-30 2007-07-24 Oklahoma Medical Research Foundation Calcium binding recombinant antibody against protein C
US5695993A (en) 1994-08-12 1997-12-09 Oklahoma Medical Research Foundation Cloning and regulation of an endothelial cell protein C/activated protein C receptor
US6953568B1 (en) 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
DE60141844D1 (de) * 2000-10-02 2010-05-27 Oklahoma Med Res Found Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000102A1 (en) * 1991-06-24 1993-01-07 The Scripps Research Institute Apc polypeptides and anti-peptide antibodies, diagnostic methods and systems for inhibitng apc, and therapeutic methods

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ALIREZA R. REZAIE, et al "The High Affinity Calcium-binding Site Involved in Protein C Activation Is Outside the First Epidermal Growth Factor Homology Domain", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 267, No. 17, Issue of June 15, 1992, pp. 11701-11704. MARTIN LAURELL, et al "Characterization of monoclonal antibodies against human protein C specific for the calcium ion-induced conformation or for the activation peptide region", FEBS LETTERS, Volume 191, number 1, October 1985, pp. 75-81. Б. Р. ГЕЛЬФАНД и др. "Применение активированного протеина С в лечении больных с тяжелым сепсисом", Инфекции в хирургии, Том 2, N1, 2004, стр. 20-27 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2824515C1 (ru) * 2021-07-13 2024-08-08 Оклахома Медикал Рисерч Фаундейшн Моноклональное антитело к активированному белку с человека и его получение и применение

Also Published As

Publication number Publication date
IL220622A0 (en) 2012-08-30
US8153766B2 (en) 2012-04-10
AU2008316661B2 (en) 2013-05-23
EP2205638A2 (en) 2010-07-14
US20090110683A1 (en) 2009-04-30
US20120164150A1 (en) 2012-06-28
CA2703738C (en) 2018-02-27
KR20150092358A (ko) 2015-08-12
JP2013049694A (ja) 2013-03-14
AU2008316661A1 (en) 2009-04-30
KR20100116166A (ko) 2010-10-29
KR101856210B1 (ko) 2018-05-09
JP2014237651A (ja) 2014-12-18
CA2703738A1 (en) 2009-04-30
EP2205638B1 (en) 2017-03-01
US20150344588A1 (en) 2015-12-03
ZA201105704B (en) 2014-05-28
US9127072B2 (en) 2015-09-08
CN101918453A (zh) 2010-12-15
RU2012150953A (ru) 2014-06-10
JP6117741B2 (ja) 2017-04-19
RU2010121148A (ru) 2011-12-10
WO2009055669A2 (en) 2009-04-30
BRPI0818865A2 (pt) 2015-05-05
JP2011500843A (ja) 2011-01-06
IL205284A0 (en) 2010-12-30
WO2009055669A3 (en) 2009-09-03
MX2010004615A (es) 2010-07-06
CN105153308A (zh) 2015-12-16
IL205284A (en) 2014-06-30
CN103232541A (zh) 2013-08-07

Similar Documents

Publication Publication Date Title
US8153766B2 (en) Monoclonal antibodies against activated protein C
JP6669800B2 (ja) Ｍａｓｐ−２依存性の補体活性化を阻害するための組成物
US20240398914A1 (en) Combination therapy using a factor xii inhibitor and a c-1 inhibitor
IL277162A (en) Monoclonal antibodies against tissue pathway inhibitor (TFPI)
US11597777B2 (en) Antibodies for the prevention or the treatment of bleeding episodes
MX2015006738A (es) Anticuerpos monoclonales humanizados contra la proteina c activada y sus usos.
AU2016203760B2 (en) Monoclonal antibodies against activated and unactivated protein c
AU2013202464B2 (en) Monoclonal antibodies against activated and unactivated protein c
AU2015200348B2 (en) Monoclonal antibodies against activated and unactivated protein c
HK1187631A (en) Monoclonal antibodies against activated and unactivated protein c